Get a Quote

OZANIMOD HYDROCHLORIDE
CAS NO.: 1618636-37-5
Chemical Formula: C23H25ClN4O3
Molecular Weight: 440.9000
DMF&GMP status: Please contact us for more details.
Description:
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene(now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26 2020. MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
OZANIMOD HYDROCHLORIDECAPSULE;ORAL0.23MGZEPOSIACELGENE INTERNATIONAL II SARL
OZANIMOD HYDROCHLORIDECAPSULE;ORAL0.46MGZEPOSIACELGENE INTERNATIONAL II SARL
OZANIMOD HYDROCHLORIDECAPSULE;ORAL0.92MGZEPOSIACELGENE INTERNATIONAL II SARL
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
848157305/14/2029DSDPU-2774
879631805/14/2029DSDP
938221705/14/2029U-2774
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 03/25/2025